RxDoctor Payments Data

Claire Reece

Psychiatric/Mental Health · Phoenix, AZNPI 1194005124

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $66,580 of the $88,290 with a category attached, or 75.4%. Johnson & Johnson accounts for 98.6% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $35,671, more than ten times the $455 reported in 2021. Among psychiatric/mental health clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$88,290in general payments, 2019–2025

Across 182 payments — averaging $485.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$87K
  • Teva Pharmaceuticals USA, Inc.$589
  • Alkermes, Inc.$243
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$136
  • Neurocrine Biosciences, Inc.$98
  • Otsuka America Pharmaceutical, Inc.$81
  • plus $111 from 3 others

What the payments were for

  • Consulting fees$5,2806%
  • Speaking & faculty fees$66,58075%
  • Travel & lodging$12,11914%
  • Food & beverage$3,8794%
  • Education$4320%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$88,290 in reported general payments places this provider in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.

See all psychiatric/mental health providers in Arizona

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate157$563,860
AustedoDeutetrabenazine15$121,224
AristadaAripiprazole Lauroxil23$76,211
IngrezzaValbenazine Tosylate31$64,006
Abilify MaintenaAripiprazole17$48,485
Fluphenazine Hcl89$9,414
Clozapine67$4,956
Fluphenazine Decanoate29$3,116
Oxcarbazepine66$2,787
Hydroxyzine Hcl173$2,266
Haloperidol Decanoate40$2,137
Quetiapine Fumarate167$1,880
Fluvoxamine Maleate36$1,204
Divalproex Sodium ErDivalproex Sodium23$1,181
Benztropine Mesylate150$1,161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$87,032$563,860157 claims
Teva Pharmaceuticals USA, Inc.Austedo, Loxapine$589$121,73448 claims
Alkermes, Inc.Aristada$243$76,21123 claims
Neurocrine Biosciences, Inc.Ingrezza$98$64,00631 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$81$48,48517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.

Other psychiatric/mental health in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →